Role of COX-2 in lymphangiogenesis and restoration of lymphatic flow in secondary lymphedema

Laboratory Investigation

Volumn 91, Issue 9, 2011, Pages 1314-1325

  Kashiwagi, Shinya ^a   Hosono, Kanako ^a   Suzuki, Tatsunori ^a   Takeda, Akira ^a   Uchinuma, Eiju ^a   Majima, Masataka ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

COX 2; lymphangiogenesis; lymphedema; LYVE 1; VEGF C

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; PROSTAGLANDIN E2; VASCULOTROPIN A; VASCULOTROPIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; GRANULATION TISSUE; HUMAN; HUMAN CELL; LYMPH FLOW; LYMPH VESSEL; LYMPHANGIOGENESIS; LYMPHEDEMA; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; WOUND;

ANIMALS; BASE SEQUENCE; CYCLOOXYGENASE 2; DNA PRIMERS; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; LYMPHEDEMA; MALE; MICE; MICE, INBRED C57BL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; WOUND HEALING;

EID: 80052283479     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2011.84     Document Type: Article

References (43)

1. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005;438:946-953. (Pubitemid 43093960)
2. Tammela T, Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 2010;140:460-476.
3. Erickson VS, Pearson ML, Ganz PA, et al. Arm edema in breast cancer patients. J Natl Cancer Inst 2001;93:96-111. (Pubitemid 32111987)
4. Petrek JA, Senie RT, Peters M, et al. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer 2001;92:1368-1377. (Pubitemid 32947819)
5. Carter BJ. Women's experiences of lymphedema. Oncol Nurs Forum 1997;24:875-882.
6. Logmans A, Kruyt RH, de Bruin HG, et al. Lymphedema and lymphocysts following lymphadenectomy may be prevented by omentoplasty: a pilot study. Gynecol Oncol 1999;75:323-327.
7. Oliver G, Alitalo K. The lymphatic vasculature: recent progress and paradigms. Annu Rev Cell Dev Biol 2005;21:457-483. (Pubitemid 41740643)
8. Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell 1999;98:769-778. (Pubitemid 29446894)
9. Karkkainen MJ, Saaristo A, Jussila L, et al. A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci USA 2001;98:12677-12682. (Pubitemid 33020005)
10. Majima M, Isono M, Ikeda Y, et al. Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants. Jpn J Pharmacol 1997;75:105-114. (Pubitemid 27491544)
11. Majima M, Hayashi I, Muramatsu M, et al. Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol 2000;130:641-649. (Pubitemid 30332983)
12. Amano H, Hayashi I, Endo H, et al. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 2003;197:221-232. (Pubitemid 36152316)
13. Majima M, Amano H, Hayashi I. Prostanoid receptor signaling relevant to tumor growth and angiogenesis. Trends Pharmacol Sci 2003;24:524-529. (Pubitemid 37244005)
14. Kubo H, Hosono K, Suzuki T, et al. Host prostaglandin EP3 receptor signaling relevant to tumor-associated lymphangiogenesis. Biomed Pharmacother 2010;64:101-106.
15. Katoh H, Hosono K, Ito Y, et al. COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems. Am J Pathol 2010;176:1469-1483.
16. Hagendoorn J, Padera TP, Kashiwagi S, et al. Endothelial nitric oxide synthase regulates microlymphatic flow via collecting lymphatics. Circ Res 2004;95:204-209. (Pubitemid 38988687)
17. Kawamoto T. Use of a new adhesive film for the preparation of multipurpose flesh-frozen sections from hard tissues, whole-animals, insects and plants. Arch Histol Cytol 2003;66:123-143. (Pubitemid 36834422)
18. Schneider M, Ny A, de Almodovar CR, et al. A new mouse model to study acquired lymphedema. PLoS Med 2006;3:e264.
19. Cheung L, Han J, Beilhack A, et al. An experimental model for the study of lymphedema and its response to therapeutic lymphangiogenesis. BioDrugs 2006;20:363-370. (Pubitemid 46089663)
20. Jin da P, An A, Liu J, et al. Therapeutic responses to exogenous VEGF-C administration in experimental lymphedema: immunohistochemical and molecular characterization. Lymphat Res Biol 2009;7:47-57.
21. Fö ldi E, Sauerwald A, Hennig B. Effect of complex decongestive physiotherapy on gene expression for the inflammatory response in peripheral lymphedema. Lymphology 2000;33:19-23. (Pubitemid 30198825)
22. Angeli V, Randolph GJ. Inflammation, lymphatic function, and dendritic cell migration. Lymphat Res Biol 2006;4:217-228. (Pubitemid 46493659)
23. Haarbrink M, Terhell AJ, Abadi GK, et al. Inflammatory cytokines following diethylcarbamazine (DEC) treatment of different clinical groups in lymphatic filariasis. Trans R Soc Trop Med Hyg 1999;93: 665-672. (Pubitemid 30015801)
24. Faour WH, Gomi K, Kennedy CR. PGE2 induces COX-2 expression in podocytes via the EP4 receptor through a PKA-independent mechanism. Cell Signal 2008;20:2156-2164.
25. Rö sch S, Ramer R, Brune K, et al. Prostaglandin E2 induces cyclooxygenase-2 expression in human non-pigmented ciliary epithelial cells through activation of p38 and p42/44 mitogenactivated protein kinases. Biochem Biophys Res Commun 2005;338: 1171-1178. (Pubitemid 41597760)
26. Hinz B, Brune K, Pahl A. Prostaglandin E2 upregulates cyclooxygenase-2 expression in lipopolysaccharide-stimulated RAW 264.7 macrophages. Biochem Biophys Res Commun 2000;272:744-748. (Pubitemid 30420710)
27. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004; 113:1040-1050. (Pubitemid 38544126)
28. Su JL, Shih JY, Yen ML, et al. Cyclooxygenase-2 induces EP1-and HER-2/Neudependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res 2004;64:554-564.
29. von Rahden BH, Stein HJ, Puhringer F, et al. Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res 2005;65:5038-5044. (Pubitemid 40827311)
30. Timoshenko AV, Chakraborty C, Wagner GF, et al. COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br J Cancer 2006;94:1154-1163.
31. Nakamura K, Radhakrishnan K, Wong YM, et al. Anti-inflammatory pharmacotherapy with ketoprofen ameliorates experimental lymphatic vascular insufficiency in mice. PLoS One 2009;4:e8380.
32. Ueno T, Suzuki T, Oikawa A, et al. Recruited bone marrow cells expressing the EP3 prostaglandin E receptor subtype enhance angiogenesis during chronic inflammation. Biomed Pharmacother 2010;64:93-100.
33. Kamoshita E, Ikeda Y, Fujita M, et al. Recruitment of a prostaglandin E receptor subtype, EP3-expressing bone marrow cells is crucial in wound-induced angiogenesis. Am J Pathol 2006;169:1458-1472. (Pubitemid 351194377)
34. Amano H, Ando K, Minamida S, et al. Adenylate cyclase/protein kinase A signaling pathway enhances angiogenesis through induction of vascular endothelial growth factor in vivo. Jpn J Pharmacol 2001;87:181-188.
35. Orlandini M, Oliviero S. In fibroblasts Vegf-D expression is induced by cellcell contact mediated by cadherin-11. J Biol Chem 2001;276:6576-6581.
36. Mitchell PJ, Wang C, Tjian R. Positive and negative regulation of transcription in vitro: enhancer-binding protein AP-2 is inhibited by SV40 T antigen. Cell 1987;50:847-861.
37. Imagawa M, Chiu R, Karin M. Transcription factor AP-2 mediates induction by two different signal-transduction pathways: protein kinase C and cAMP. Cell 1987;51:251-260.
38. Orlandini M, Marconcini L, Ferruzzi R, et al. Identification of a c-fosinduced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proc Natl Acad Sci USA 1996;93:11675-11680.
39. Radhakrishnan K, Rockson SG. The clinical spectrum of lymphatic disease. Ann NY Acad Sci 2008;1131:155-184. (Pubitemid 351758512)
40. Baumeister RG, Seifert J, Wiebecke B, et al. Experimental basis and first application of clinical lymph vessel transplantation of secondary lymphedema. World J Surg 1981;5:401-407. (Pubitemid 11005339)
41. Saaristo A, Tammela T, Timonen J, et al. Vascular endothelial growth factor-C gene therapy restores lymphatic flow across incision wounds. FASEB J 2004;18:1707-1709. (Pubitemid 39561658)
42. Karkkainen MJ, Saaristo A, Jussila L, et al. A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci USA 2001;98:12677-12682. (Pubitemid 33020005)
43. Saaristo A, Veikkola T, Tammela T, et al. Lymphangiogenic gene therapy with minimal blood vascular side effects. J Exp Med 2002;196:719-730.